BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 32965582)

  • 21. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
    Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus.
    Zhang Y; Wu JL; Li LQ
    Ann Hepatol; 2022; 27(1):100552. PubMed ID: 34614432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion.
    Li JR; Wu MJ; Wang T; Tian M; Zhou G; Liu QX; Xiang XH; Zhang YQ
    Abdom Radiol (NY); 2021 May; 46(5):1967-1976. PubMed ID: 33386450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study.
    Yuan J; Yin X; Tang B; Ma H; Zhang L; Li L; Chen R; Xie X; Ren Z
    Biomed Res Int; 2019; 2019():2141859. PubMed ID: 31467872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
    Zhang ZH; Liu QX; Zhang W; Ma JQ; Wang JH; Luo JJ; Liu LX; Yan ZP
    World J Gastroenterol; 2017 Nov; 23(43):7735-7745. PubMed ID: 29209114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reappraisal of Portal Vein Tumor Thrombosis as a Prognostic Factor for Patients with Hepatocellular Carcinoma.
    Chang Y; Yu SJ; Kim HC; Lee YB; Cho EJ; Lee JH; Kim YJ; Chung JW; Yoon JH
    Gut Liver; 2024 Jan; 18(1):156-164. PubMed ID: 38013475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
    Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
    World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study.
    Wang J; Li X; Wang F; Shi D; Zhang J
    J Cancer Res Ther; 2021 Jul; 17(3):619-624. PubMed ID: 34269290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
    Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
    Kim GA; Shim JH; Yoon SM; Jung J; Kim JH; Ryu MH; Ryoo BY; Kang YK; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    J Vasc Interv Radiol; 2015 Mar; 26(3):320-9.e6. PubMed ID: 25612807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Portal Vein Irradiation Stent Plus Chemoembolization versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study.
    Tan Z; Lu J; Zhu G; Chen L; Wang Y; Zhang Q; Pan T; Wang J; Guo J; Teng G
    Cardiovasc Intervent Radiol; 2021 Sep; 44(9):1414-1422. PubMed ID: 34131776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
    Zhong BY; Ni CF; Chen L; Zhu HD; Teng GJ
    Radiology; 2017 Aug; 284(2):583-592. PubMed ID: 28263701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification.
    Niu ZJ; Ma YL; Kang P; Ou SQ; Meng ZB; Li ZK; Qi F; Zhao C
    Med Oncol; 2012 Dec; 29(4):2992-7. PubMed ID: 22200992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi-institutional propensity-matched cohort study.
    Komatsu S; Ueshima K; Kido M; Kuramitsu K; Tsugawa D; Yanagimoto H; Toyama H; Ku Y; Kudo M; Fukumoto T
    J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):303-314. PubMed ID: 36047804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang XP; Wang K; Li N; Zhong CQ; Wei XB; Cheng YQ; Gao YZ; Wang H; Cheng SQ
    BMC Cancer; 2017 Dec; 17(1):902. PubMed ID: 29282010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic value of transcatheter arterial chemoembolization combined with portal vein embolization for primary hepatocellular carcinoma with portal vein tumor thrombus: a pilot study.
    Tan X; Xie P; Liu J; Wu H; Xie Y
    Asia Pac J Clin Oncol; 2015 Sep; 11(3):e6-e12. PubMed ID: 25228074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma.
    Zhao Y; Duran R; Chapiro J; Sohn JH; Sahu S; Fleckenstein F; Smolka S; Pawlik TM; Schernthaner R; Zhao L; Lee H; He S; Lin M; Geschwind JF
    J Gastrointest Surg; 2016 Dec; 20(12):2002-2009. PubMed ID: 27714643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.